Single-center, Open Label Trial of ACTEMRA (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)
Latest Information Update: 16 Apr 2024
Price :
$35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Neuromyelitis optica
- Focus Therapeutic Use
- 10 Apr 2024 Eligibility criteria amended to include subjects from 18 to 75 years.
- 15 Oct 2018 Status changed from active, no longer recruiting to completed.
- 02 Mar 2017 New trial record